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ABSTRACT
Background: In randomized controlled trials, Ginkgo biloba extract EGb 761® has been found to be effective
in the treatment of behavioral and psychological symptoms of dementia (BPSD).
Methods: To assess the effects of EGb 761® on specific BPSD, we analyzed data from all randomized, placebo-
controlled, at least 20-week, trials of EGb 761® enrolling patients with dementia (probable Alzheimer’s
disease (AD), probable vascular dementia or probable AD with cerebrovascular disease) who had clinically
significant BPSD (Neuropsychiatric Inventory (NPI) total score at least 6). Data were pooled and joint
analyses of NPI single item composite and caregiver distress scores were performed by meta-analysis with
a fixed effects model.
Results: Four trials involving 1628 patients (EGb 761®, 814; placebo, 814) were identified; treatment
duration was 22 or 24 weeks; the daily dose of EGb 761® was 240 mg in all trials. Pooled analyses including
data from the full analysis sets of all trials (EGb 761®, 796 patients; placebo, 802 patients) revealed significant
superiority of EGb 761® over placebo in total scores and 10 single symptom scores. Regarding caregiver
distress scores, EGb 761®-treated patients improved significantly more than those receiving placebo in all
symptoms except delusions, hallucinations, and elation/euphoria. The benefit of EGb 761® mainly consists
of improvement in symptoms present at baseline, but the incidence of some symptoms was also decreased.
Conclusions: Twenty two- to twenty four-week treatment withGinkgo biloba extract EGb 761® improved BPSD
(except psychotic-like features) and caregiver distress caused by such symptoms.
Key words: dementia, behavioral and psychological symptoms, BPSD, Ginkgo biloba, EGb 761®, systematic review, meta-analysis
Introduction
Behavioral and psychological symptoms
of dementia (BPSD; also referred to as
neuropsychiatric symptoms, NPS) are common
manifestations of Alzheimer’s disease (AD) as well
as vascular dementia (VaD; Lyketsos et al., 2000).
They adversely affect the patients’ quality of life
(Karttunen et al., 2011), cause distress to caregivers
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(Cummings and McPherson, 2001), increase the
risk for nursing home placement (Tun et al., 2007),
and increase the cost of care (Jönsson et al., 2006).
The presence of BPSD has also been reported to
predict the progression to severe dementia in AD.
Whereas in older diagnostic systems (McKhann
et al., 1984; Román et al., 1993) such symptoms
were classified as merely “consistent” with a
diagnosis of AD or VaD, they are now listed
among the “core clinical criteria” for all-cause
dementia (McKhann et al., 2011), reflecting a
changing view about the clinical significance of
these symptoms. BPSD are therefore a major target
for treatment in patients with dementia. Beneficial
effects have been reported for some anti-dementia
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drugs (cholinesterase inhibitors, memantine),
anti-depressants (Gauthier et al., 2010), and some
antipsychotics (Tan et al., 2015). Specific effects of
citalopram in patients with agitation associated with
AD have been reported (Porsteinsson et al., 2014).
A recently published systematic review (von
Gunten et al., 2016) identified four large, ran-
domized, placebo-controlled, double-blind, multi-
center trials of the defined, quantified Ginkgo
biloba extract EGb 761® in patients with mild to
moderate dementia who had clinically significant
BPSD. (EGb 761® is a dry extract from Ginkgo
biloba leaves (35–67:1), extraction solvent: acetone
60% (w/w). The extract is adjusted to 22.0%–
27.0% ginkgo flavonoids calculated as ginkgo
flavone glycosides and 5.0%–7.0% terpene lactones
consisting of 2.8%–3.4% ginkgolides A, B, C,
and 2.6%–3.2% bilobalide and contains less than
5 ppm ginkgolic acids.) In two 22-week trials,
the Neuropsychiatric Inventory (NPI; Cummings,
1997) was used as secondary outcome measure,
showing significant superiority of EGb 761® over
placebo in one trial and a tendency favoring active
treatment in the other (Napryeyenko et al., 2007;
Nikolova et al., 2013). In two 24-week trials, change
in the NPI composite score was prospectively
defined as co-primary outcome and the caregiver
distress score was a secondary outcome. In both
trials, EGb 761® was significantly superior to
placebo in composite scores as well as caregiver
distress ratings (Ihl et al., 2011; Herrschaft et al.,
2012).
The objective of this meta-analysis was to
examine the treatment effects of EGb 761® on
single behavioral and psychological symptoms with
regard to overall reduction of symptoms, reduction
of symptoms present at baseline, the prevention
of newly emerging symptoms and implications for
caregiver burden.
Patients and methods
Eligibility criteria, data sources, and search
Randomized, placebo-controlled clinical trials of
EGb 761® with a minimal duration of 20 weeks,
including patients with dementia (probable AD,
probable VaD or possible AD with cerebrovascular
disease) who had clinically significant BPSD (NPI
total score at least 6) were identified.
We used a sensitive search strategy including the
following electronic databases: PubMed, including
MedLine (from beginning to December 2013),
EMBASE (from January 2006 to December 2013),
and PASCAL (from beginning to December
2013). The following search terms were used
(with * characterizing a wildcard, and the items
AND and OR being used as Boolean functions):
(ginkg* OR gingk*) AND clinical trial(pt) for
PubMed including MedLine, ((ginkg* OR gingk*)
NOT medline(sb)) AND (clinical* OR trial OR
randomized) for PubMed excluding Medline,
(GINKGO OR GINGKO), AND (HUMAN/CT
OR HOMME/CTFR) for PASCAL, and (ginkgo
or gingko) AND CT = (CLINICAL TRIAL;
CLINICAL STUDY; DOUBLE BLIND PRO-
CEDURE) AND py > 2005 for EMBASE.
A search update was conducted in June 2016.
Furthermore, the reference sections of systematic
reviews were screened for primary publications.
In addition, the manufacturer of EGb 761®, Dr.
Willmar Schwabe GmbH & Co. KG, was asked
about studies that were not identified by the search
or had not been published when the search was
performed.
Selection and critical appraisal of clinical
trials
Two persons independently from each other
screened the results of the literature search and
the retrieved full papers for eligibility. Their
judgments were concordant; no discrepancies had
to be resolved. Trial and publication quality
were assessed in terms of randomization and
allocation concealment, blinding of patients and
investigators, sample size estimation, proportion of
trial discontinuations, application of the intent-to-
treat principle and whether statistical analyses were
reported and judged adequate. All included trials
adequately met these quality criteria.
Four eligible studies were identified by the
original database search; no further relevant study
was identified by the search update or by the manu-
facturer. The four trials were randomized, placebo-
controlled, double-blind, multi-center, parallel-
group trials performed independently of each
other in adherence to the provisions for Good
Clinical Practice (GCP) set by the International
Conference on Harmonization and the World
Medical Association’s Declaration of Helsinki.
For all trials, approval by regulatory bodies and
ethics committees was obtained and patients were
enrolled only after written informed consent had
been received. The methods and main results
have been reported in the primary publications
in peer-reviewed journals (GINDEM-NP Study:
Napryeyenko et al., 2007; GOTADAY Study: Ihl
et al., 2011; GOT-IT! Study: Herrschaft et al.,
2012; PLAGIN Study: Nikolova et al., 2013).
All four trials were similarly designed and
enrolled patients with mild to moderate dementia
who scored 35 or less in the Test for the Early
Detection of Dementia with Differentiation from
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Depression (Mahoney et al., 2005) and 9 to 23
on the SKT short cognitive performance test (Kim
et al., 1993) and had clinically significant BPSD,
as shown by a composite score of at least 6 on
the NPI, with at least one item score (other than
delusions or hallucinations) of at least 3. Diagnoses
of probable AD, probable VaD or possible AD
with cerebrovascular disease were established using
the research diagnostic criteria by McKhann et al.
(1984) and/or Román et al. (1993), as applicable.
In accordance with random allocation, patients
received Ginkgo biloba extract EGb 761® at a daily
dose of 240 mg or matching placebo tablets for
periods of 22 weeks (GINDEM-NP, PLAGIN) or
24 weeks (GOTADAY, GOT-IT!). The primary
outcome measure in all studies was the change
in the SKT total score. The change in the NPI
composite score was co-primary in the two 24-
week trials and a secondary outcome in the 22-
week trials. Scales for activities of daily living, global
ratings, and quality-of-life scales (in 24-week trials
only) were recorded as secondary outcomes.
Outcomes
Outcomes of interest for this meta-analysis were
the single items of the NPI. The NPI is a 12-
item inventory to assess the presence and severity of
behavioral changes in patients with dementia. The
ratings of frequency, severity, and related caregiver
distress are based on an interview of the clinician
with the patient’s caregiver. The twelve symp-
toms/disorders assessed are delusions, hallucin-
ations, agitation/aggression, depression/dysphoria,
anxiety, elation/euphoria, apathy/indifference, dis-
inhibition, irritability/lability, aberrant motor beha-
vior, sleep and nighttime behavior disorders, ap-
petite and eating disorders. Each symptom/disorder
is rated by frequency (range: 1 to 4) and severity
(range: 1 to 3); a composite score is formed by
multiplying the scores for frequency and severity
(range: 1 to 12). In addition, caregiver distress is
rated along a scale ranging from 0 to 5. Higher
scores indicate more impairment.
Statistical analysis
For all selected trials, individual participant data
were provided by Dr. Willmar Schwabe GmbH &
Co KG. For each of the four clinical trials the
effects of EGb 761® were compared to placebo
with respect to the total composite score, the
total caregiver distress score and their respective
12 single items. For the overall reduction of
symptoms and the reduction of symptoms present
at baseline (including patients with symptoms in
the respective item at baseline), an analysis of
covariance (ANCOVA) model was used to calculate
the changes from baseline to week 22/24. The
ANCOVA model included terms for treatment
group and baseline value of respective outcome
variable as covariates (stage 1). The resulting least
square means (LSM) and standard deviations of
each study were combined in a fixed effect meta-
analysis (summary measure: weighted difference
in LSM (LSMD) and 95% confidence limit for
the changes from baseline to 22/24 week follow-
up for the EGb 761® treatment group compared
to the placebo group; negative LSMDs show an
advantage of the EGb 761® treatment group; stage
2). The fixed effects model using the inverse
variance method was chosen due to the similar
design, nearly identical inclusion and exclusion
criteria, daily doses, and duration of treatment of
the four included studies.
Furthermore, for each study, the incidence of
newly emerging symptoms (represented by the
respective item of the NPI, separately for each
item) from baseline to 22/24 week follow-up was
calculated under EGb 761® and placebo in patients
with a baseline value of 0 for the respective
symptom (i.e. respective symptom not present at
baseline; stage 1). To assess the potential for
prevention of newly emerging symptoms by EGb
761® compared to placebo, weighted relative risks
(RR) and 95% CI were calculated by a meta-
analysis for binary data using a fixed effects model
to combine results of the four clinical trials (EGb
761® treatment compared to placebo; stage 2). RR
below 1 shows an advantage of the EGb 761®
treatment group.
To assess the clinical relevance of treatment
effects of EGb 761® for the twelve single items
of the NPI (each for composite and caregiver
distress scores), standardized mean differences
(SMD) were calculated for the results of the meta-
analyses (SMD = LSMD/standard deviation) in
those patients in whom the respective symptoms
were present at baseline. Cohen (1992) defined an
SMD of 0.5 (reflected by the interval from 0.4 to
0.6) as medium effect size, SMDs below 0.4 as
small and SMDs above 0.6 as large effects.
All outcomes were assessed in the intention-to-
treat/full-analysis sets. The last observation during
randomized treatment was carried forward (LOCF)
for missing values of the outcome variables on a
single item basis. The maximum of missing values
replaced by LOCF for a single item was 3.2%.
The meta-analyses were performed using the
package “meta” in R (Version 3.1.0). As all items
have equal weight in the composite and caregiver
score, no item was selected as primary outcome. In
all analyses, statistical significance was assumed if
p< 0.05 as adjustment for multiple testing is not
routinely used in meta-analyses.
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Table 1. Baseline composite and caregiver distress scores of the patients in the pooled data set; means ±
standard deviations
EGb 761® (N = 796) placebo (N = 802)
composite caregiver distress composite caregiver distress
scores scores scores scores
............................................................................................................................................................................................................................................................................................................................
Total scores 17.87 (8.78) 10.84 (6.18) 18.06 (8.62) 10.74 (5.76)
Delusions 0.16 (0.77) 0.14 (0.60) 0.21 (0.94) 0.18 (0.70)
Hallucinations 0.05 (0.35) 0.06 (0.39) 0.05 (0.39) 0.05 (0.34)
Agitation/aggression 1.03 (1.69) 0.82 (1.26) 1.01 (1.73) 0.78 (1.23)
Depression/dysphoria 1.93 (1.91) 1.34 (1.24) 2.00 (2.02) 1.35 (1.27)
Anxiety 2.81 (2.21) 1.71 (1.26) 2.90 (2.31) 1.74 (1.23)
Elation/euphoria 0.34 (1.13) 0.18 (0.64) 0.36 (1.23) 0.20 (0.66)
Apathy/indifference 3.45 (2.72) 1.79 (1.31) 3.44 (2.79) 1.76 (1.33)
Disinhibition 0.71 (1.53) 0.56 (1.10) 0.73 (1.61) 0.54 (1.09)
Irritability/lability 2.74 (2.36) 1.77 (1.33) 2.76 (2.35) 1.77 (1.32)
Aberrant motor behavior 0.84 (1.99) 0.49 (1.07) 0.84 (1.98) 0.48 (1.04)
Sleep/nighttime behavior 3.15 (2.45) 1.65 (1.30) 3.05 (2.37) 1.57 (1.27)
Appetite/eating 0.66 (1.75) 0.33 (0.86) 0.71 (1.78) 0.32 (0.79)
Results
A total of 1628 patients were randomized to the
four trials. Of these, 1,598 patients (98%) had ef-
ficacy data after baseline (EGb 761®, 796; placebo
802). At baseline, there were no conspicuous
differences between treatment groups with respect
to demographic characteristics (mean age 66 years,
standard deviation nine years, in both treatment
groups; 67% and 68% females in EGb 761® and
placebo group, respectively) and severity of BPSD
(Table 1). Aberrant sleep/nighttime behavior (n =
1250), apathy (n = 1240), anxiety (n = 1231),
irritability (n = 1168) and depression/dysphoria
(n = 1015) were the most prevalent symptoms at
baseline.
Net changes between baseline and end of
treatment for both composite and caregiver distress
total scores were significantly larger in the patients
treated with EGb 761® than in those receiving
placebo. Regarding the single item composite
scores, most pronounced net effects were found for
apathy (LSMD −0.82; 95% CI −1.00 to −0.64),
sleep/nighttime behavior (−0.64; −0.80 to −0.47),
depression (−0.59; −0.72 to −0.46), anxiety
(−0.58; −0.73 to −0.43), and irritability/lability
(−0.48; −0.63 to −0.33), p< 0.001 for all in favor
of EGb 761® compared to placebo (Figure 1).
Similarly, net effects on the caregiver distress
scale were largest for depression (LSMD −0.40;
95% CI −0.48 to −0.31), sleep/nighttime behavior
(−0.38; −0.46 to −0.29), apathy (−0.37; −0.46
to −0.28), anxiety (−0.36; −0.45 to −0.27),
and irritability/lability (−0.28; −0.37 to −0.19),
p< 0.001 for all in favor of EGb 761® compared
to placebo (Figure 2). There was little change in
delusions, hallucinations, or elation/euphoria, the
items with very low baseline scores (Figures 1 and
2). The I2 statistic, which quantifies the amount of
variation in the results across the studies, ranged
from 0% to 97% in the meta-analyses.
Mean improvement of EGb 761® treatment
compared to placebo for symptoms present at
baseline (respective NPI item score > 0) was
most pronounced in aberrant motor behavior
(LSMD −1.05, 95% CI −1.43 to −0.67), apathy
(−0.96; −1.17 to −0.74), depression (−0.83;
−1.03 to −0.64), agitation (−0.82; −1.10 to
−0.54), sleep/nighttime behavior (−0.78; −0.98
to −0.58), and anxiety (−0.74; −0.92 to −0.56),
p< 0.001 for all in favor of EGb 761® compared
to placebo (Figure 3). Caregiver distress was
reduced most distinctly with regard to the same
symptoms, although in slightly different sequence:
agitation (LSMD −0.62; 95% CI −0.80 to
−0.44), depression (−0.57; −0.69 to −0.44),
aberrant motor behavior (−0.50; −0.70 to −0.30),
sleep/nighttime behavior (−0.49; −0.59 to −0.38),
anxiety (−0.48; −0.59 to −0.38), and apathy
(−0.42; −0.53 to −0.31), p< 0.001 for all in favor
of EGb 761® compared to placebo (Figure 4).
Effect sizes (in favor of EGb 761® treatment) for
these six items were classified as medium according
to Cohen’s concept, with SMDs between 0.44 and
0.59 in composite scores and caregiver distress
scores.
Improvements in symptoms that were present at
baseline were more frequently observed in patients
treated with EGb 761® than in those receiving
placebo (Table 2).
The incidence of symptoms not present
at baseline was significantly lower in EGb
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Figure 1. Overall effects of EGb 761® on symptom frequency/severity.
Figure 2. Overall effects of EGb 761® on caregiver distress.
761®-treated patients than in those receiving
placebo for depression (risk ratio 0.36, (95%
CI 0.22 to 0.60); p< 0.001), apathy (0.46
(0.28 to 0.75); p = 0.002), disinhibition (0.37
(0.21 to 0.67); p = 0.001) and disturbance of
sleep/nighttime behavior (0.56 (0.34 to 0.93); p =
0.258). This was associated with lower rates of in-
cident caregiver distress related to these symptoms.
The risk ratios and 95% confidence intervals were
0.33 (0.20 to 0.55) for depression (p< 0.001), 0.63
(0.43 to 0.94) for apathy (p = 0.022), 0.43 (0.25 to
0.76) for disinhibition (p = 0.004), and 0.48 (0.30
to 0.79) for sleep/nighttime behavior (p = 0.004)
in favor of EGb 761® compared to placebo.
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Figure 3. Improvement of symptom frequency/severity.
Figure 4. Improvement of caregiver distress.
Discussion
In four randomized, placebo-controlled trials, the
efficacy of the quantified Ginkgo biloba extract EGb
761® was tested in patients who were suffering from
dementia with clinically significant BPSD. Overall,
in 9 out of 12 symptoms covered by the NPI
significant benefits of EGb 761® in comparison
to placebo could be demonstrated simultaneously
for composite and caregiver distress over a period
of 22 to 24 weeks. Although there was some
heterogeneity with regard to effect sizes, the pattern
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Table 2. Numbers and percentages of patients who improved in symptoms that were present at baseline
(number improved/number with symptom present at baseline (% improved))
EGb 761® placebo
composite caregiver distress composite caregiver distress
scores scores scores scores
............................................................................................................................................................................................................................................................................................................................
Delusions 30/46 (65.2%) 29/45 (64.4%) 24/54 (44.4%) 28/53 (52.8%)
Hallucinations 12/19 (63.2%) 11/19 (57.9%) 10/19 (52.6%) 11/18 (61.1%)
Agitation/aggression 149/273 (54.6%) 152/266 (57.1%) 98/265 (37.0%) 90/259 (34.8%)
Depression/dysphoria 302/503 (60.0%) 277/487 (56.9%) 195/512 (38.1%) 177/491 (36.1%)
Anxiety 359/611 (58.8%) 327/592 (55.2%) 247/620 (39.8%) 204/604 (33.8%)
Elation/euphoria 44/86 (51.2%) 33/73 (45.2%) 37/91 (40.7%) 35/78 (44.9%)
Apathy/indifference 315/624 (50.5%) 270/601 (44.9%) 168/616 (27.3%) 153/588 (26.0%)
Disinhibition 96/192 (50.0%) 90/187 (48.1%) 73/188 (38.8%) 69/184 (37.5%)
Irritability/lability 306/575 (53.2%) 277/569 (48.7%) 192/593 (32.4%) 178/581 (30.6%)
Aberrant motor Behavior 87/162 (53.7%) 73/157 (46.5%) 50/169 (29.6%) 44/160 (27.5%)
Sleep/nighttime behavior 337/630 (53.5%) 313/586 (53.4%) 213/620 (34.4%) 194/574 (33.8%)
Appetite/eating 83/133 (62.4%) 81/122 (66.4) 92/152 (60.5%) 87/138 (63.0%)
of effects was remarkably consistent across the
studies (cf. Scripnikov et al., 2007; Bachinskaya
et al., 2011; Nacu and Hoerr, 2016).
To assess the clinical relevance of treatment
effects, the same analyses were repeated in those
patients in whom the respective symptoms were
present at baseline. Composite score and caregiver
distress score effect sizes were in the mod-
erate range for apathy/indifference, disturbance
of sleep/nighttime behavior, depression/dysphoria,
anxiety, agitation, and aberrant motor behavior.
For two symptoms that were less prevalent,
agitation/aggression (n = 538) and aberrant motor
behavior (n = 331), these analyses brought to light
considerable effects on composite and caregiver
distress scores, which were hidden in the overall
analyses due to rather low average baseline values
of these single items in the total population. For
the symptoms that were most prevalent at baseline
improvements were observed in 50% to 60% of
the patients treated with EGb 761® and in 30%
to 40% of those receiving placebo. Moreover, the
risk of developing symptoms not present at baseline
was reduced by more than 60% for depression and
disinhibition, and approximately halved for apathy
and disturbance of sleep/nighttime behavior in EGb
761®-treated patients compared to placebo-treated
patients.
Our findings are in line with those reported
from former studies of EGb 761® in dementia
(summarized by Hoerr, 2003) and vascular
cognitive impairment (Halama et al., 1988) that
did not specifically enroll patients with BPSD,
but accepted those with mild BPSD rather than
excluding them. In these earlier studies, like in
those reported here, depression, anxiety, irritability,
emotional lability, and motivation were improved
by EGb 761®, but the profile of effects was less
pronounced. This may be due to the milder average
severity of the disease and the different properties
of the rating scales used. An earlier meta-analysis
of EGb 761® trials found no significant effect on
neuropsychiatric and behavioral symptoms overall,
but the authors acknowledge that they included
trials in “non-depressed and non-behaviorally
disturbed patients” and that there were significant
differences in favor of EGb 761® in the two studies
included in the present meta-analysis and which
enrolled patients with clinically significant BPSD
(Weinmann et al., 2010).
The broad spectrum of effects of EGb 761® on
BPSD probably reflects its complex pattern of phar-
macodynamic activity, involving neuroprotection,
enhancement of neurogenesis, and synaptogenesis,
as well as modulation of neurotransmitter systems
(Hoerr, 2003; Tchantchou et al., 2009). The pre-
cise neurobiological mechanisms underlying each
single BPSD remain to be elucidated. Basically,
degeneration of neurons and synaptic connections
result in a weakening of neuronal circuits and
an imbalance of neurotransmitters, which entail
both cognitive and emotional dysfunction (Geda
et al., 2013). Serotonergic effects of EGb 761®
may play a role in the improvement of depression;
inhibition of the stress axis may have an influence
on anxiety (Hoerr, 2003). Aberrant behaviors,
such as agitation, aberrant motor behavior, and
disturbed nighttime behavior may be due, to
some extent, to cognitive impairment which
results in misinterpretation of the environment and
misunderstanding of other persons’ behavior or
verbal and facial expressions (Geda et al., 2013).
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Improvement in cognitive domains involved in
the recognition and interpretation of surroundings
may therefore entail an improvement in aberrant
behaviors.
One strength of the present analyses is the
underlying (pooled) sample of approximately 1,600
patients with mild to moderate dementia who were
selected using nearly identical eligibility criteria and
who had NPI ratings at onset and end of 22- to 24-
week treatment. Another strength of the data pool is
that it comes from multi-center trials that involved
sites in five European countries. It therefore seems
reassuring that the profile of effects of EGb 761® is
rather consistent across the studies.
One limitation of our study is the restriction
to databases in English language when searching
for relevant studies, although further studies may
have been conducted in Asian countries. A search
of Chinese and Japanese databases run by others
for a different type of systematic review did,
however, not bring to light any additional studies
eligible for the present meta-analysis (Hyde et al.,
2016). Another limitation is the relatively small
number of patients with psychotic symptoms, i.e.
delusions and hallucinations. This may be related to
the fact that only outpatients with mild to moderate
dementia were included in the studies and these
symptoms are primarily observed in more severe
forms of dementia. Although such symptoms may
be very burdensome to caregivers, a treatment
effect could not be shown. Elation is generally rare
in patients with dementia, and so it was in the
included trials.
Some improvement of BPSD has been reported
for other anti-dementia drugs (Gauthier et al.,
2005; Rodda et al., 2009), yet the overall effect sizes
found in these meta-analyses appear smaller than
those found for EGb 761®. However, in a study
that directly compared EGb 761® and donepezil
in patients with mild to moderate AD, essentially
similar improvements were observed (Yancheva
et al., 2009). In the absence of direct comparisons
with other drugs, any conclusion with regard to
superiority would therefore seem premature.
In summary, analyses of pooled data from four
large studies indicate that Ginkgo biloba extract
EGb 761® is an effective treatment for BPSD in
patients with mild to moderate dementia. Moderate
benefits in a broad spectrum of symptoms,
namely depression/dysphoria, agitation/aggression,
aberrant motor behavior, apathy, sleep/nighttime
behavior, anxiety, and irritability/lability were
observed in more than 50% of patients over
treatment periods of 22 to 24 weeks. In addi-
tion to improving the patients’ symptoms, EGb
761® lowers the BPSD-related distress of their
caregivers.
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